Autolus Therapeutics plc financial data

Symbol
AUTL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
The Mediaworks, 191 Wood Lane, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Autolus Therapeutics Ltd (to 6/8/2018)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.4K % +55.8%
Debt-to-equity 74.2 % -13%
Return On Equity -63.7 % +1.87%
Return On Assets -36.5 % -4.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 266M shares +53%
Entity Public Float 279M USD
Weighted Average Number of Shares Outstanding, Basic 266M shares +52.9%
Weighted Average Number of Shares Outstanding, Diluted 266M shares +52.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 145M USD +21.3%
General and Administrative Expense 83.1M USD +116%
Operating Income (Loss) -219M USD -39.2%
Nonoperating Income (Expense) -51.4M USD -9120%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -270M USD -71.2%
Income Tax Expense (Benefit) 40.5K USD -88.9%
Net Income (Loss) Attributable to Parent -270M USD -70.9%
Earnings Per Share, Basic -1.22 USD/shares -24.5%
Earnings Per Share, Diluted -1.22 USD/shares -24.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 657M USD +156%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 0 USD -100%
Assets, Current 718M USD +133%
Deferred Income Tax Assets, Net 3.39M USD +30.5%
Property, Plant and Equipment, Net 44.3M USD +27.8%
Operating Lease, Right-of-Use Asset 60.5M USD +1.85%
Assets 827M USD +104%
Accounts Payable, Current 1.42M USD +115%
Employee-related Liabilities, Current 15.4M USD +51.9%
Accrued Liabilities, Current 47.5M USD +51.3%
Liabilities, Current 52.5M USD +39.8%
Contract with Customer, Liability, Noncurrent 249M USD +76.8%
Operating Lease, Liability, Noncurrent 48.7M USD +3.61%
Other Liabilities, Noncurrent 447K USD +51.5%
Liabilities 351M USD +55.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -898K USD +97.3%
Retained Earnings (Accumulated Deficit) -1.07B USD -33.7%
Stockholders' Equity Attributable to Parent 477M USD +164%
Liabilities and Equity 827M USD +104%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.5M USD +4.49%
Net Cash Provided by (Used in) Financing Activities 561M USD
Net Cash Provided by (Used in) Investing Activities -533K USD +85.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 519M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 659M USD +156%
Deferred Tax Assets, Valuation Allowance 123M USD +28.1%
Deferred Tax Assets, Gross 126M USD +28.6%
Operating Lease, Liability 52.2M USD -0.44%
Depreciation 7.4M USD +35.7%
Payments to Acquire Property, Plant, and Equipment 533K USD -85.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -237M USD -64.4%
Lessee, Operating Lease, Liability, to be Paid 110M USD +22%
Operating Lease, Liability, Current 3.57M USD -35%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.51M USD +28.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.85M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +13.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 57.3M USD +53.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.91M USD +39.3%
Deferred Tax Assets, Operating Loss Carryforwards 105M USD +30.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.16M USD +30.4%
Operating Lease, Payments 1.73M USD +33.1%
Additional Paid in Capital 1.55B USD +52.6%
Depreciation, Depletion and Amortization 1.81M USD -4.9%
Share-based Payment Arrangement, Expense 12.5M USD +40.4%
Interest Expense 70.3M USD +282%